Qualigen Therapeutics, Inc. (QLGN)

NASDAQ: QLGN · Real-Time Price · USD
3.760
-0.120 (-3.09%)
At close: Dec 12, 2024, 4:00 PM
3.700
-0.060 (-1.60%)
After-hours: Dec 12, 2024, 4:12 PM EST
-3.09%
Market Cap 2.77M
Revenue (ttm) n/a
Net Income (ttm) -7.94M
Shares Out 736.43K
EPS (ttm) -41.53
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 37,215
Open 3.900
Previous Close 3.880
Day's Range 3.601 - 4.026
52-Week Range 3.336 - 32.500
Beta 0.15
Analysts n/a
Price Target n/a
Earnings Date Nov 14, 2024

About QLGN

Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of treatments for adult and pediatric cancer in the United States. The company’s lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase 1a clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors. Qualigen Therapeutics, Inc. was found... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1996
Employees 4
Stock Exchange NASDAQ
Ticker Symbol QLGN
Full Company Profile

Financial Performance

Financial Statements

News

Univest Securities, LLC Announces Successful Closing of $5.1 Million Private Placement for Qualigen Therapeutics, Inc. (NASDAQ: QLGN)

New York, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, tod...

17 days ago - GlobeNewsWire

Shares Expected to Begin Trading on Split-Adjusted Basis on November 5, 2024

CARLSBAD, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced today that it will implement a 1-for-50 reverse stock split of the issued share...

5 weeks ago - GlobeNewsWire

Qualigen Therapeutics, Inc. Announces management changes.

CARLSBAD, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced on September 23, 2024, Mr. Michael Poirier, notified the board of directors of...

2 months ago - GlobeNewsWire

Qualigen Therapeutics, Inc. Received Extension from Nasdaq Hearings Panel

CARLSBAD, Calif., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) today announced that on September 11, 2024, the Company received a notice from Nasdaq in...

2 months ago - GlobeNewsWire

Univest Securities, LLC Announces Closing of $3.46 Million Registered Direct Offering for its Client Qualigen Therapeutics, Inc. (NASDAQ: QLGN)

New York, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, to...

3 months ago - GlobeNewsWire

Qualigen Therapeutics, Inc. Announces Closing of $3.47 Million Public Offering

CARLSBAD, Calif., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) today announced the closing of its previously announced public offering of 14,724,058 sh...

3 months ago - GlobeNewsWire

Qualigen Therapeutics, Inc. Announces Pricing of $3.46 Million Public Offering

CARLSBAD, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) today announced the pricing of a public offering of 14,724,058 shares of common stock, p...

3 months ago - GlobeNewsWire

Qualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting Determination

CARLSBAD, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), announced today that on May 23, 2024, it received written notice (the “Delis...

7 months ago - GlobeNewsWire

Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting

Poster Includes Preclinical Data on Novel Direct Pan-RAS Inhibitors CARLSBAD, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN) today a...

8 months ago - GlobeNewsWire

Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting

CARLSBAD, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or the “Company,” Nasdaq: QLGN) today announces that a poster featuring its early clinical experience with ...

8 months ago - GlobeNewsWire

Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023

CARLSBAD, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers w...

1 year ago - GlobeNewsWire

Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors

CARLSBAD, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers w...

1 year ago - GlobeNewsWire

Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer

Poster Includes Preclinical Data on Pan-RAS Compounds Demonstrating Inhibition in Breast Cancer Models

1 year ago - GlobeNewsWire

Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023

Two p osters include data on potential clinical biomarkers and transcriptomic data associated with QN-302's mechanism of action

1 year ago - GlobeNewsWire

Qualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid Tumors

CARLSBAD, Calif., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers w...

1 year ago - GlobeNewsWire

Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023

Investigational New Drug (IND) clearance transitions Qualigen from preclinical to clinical-stage company Company divests FastPack ® diagnostics business for approximately $5 mi llion in all cash trans...

1 year ago - GlobeNewsWire

Qualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors

Investigational New Drug (IND) clearance transitions Qualigen Therapeutics from preclinical to clinical-stage company and d emonstrates leadership in G4-targeting therapies for areas of high unmet nee...

1 year ago - GlobeNewsWire

Qualigen Therapeutics Divests FastPack® Diagnostics Business

All cash deal with Chembio Diagnostics, a US Subsidiary of the French Diagnostics Company BIOSYNEX, SA, solidifies Qualigen's strategic priority on therapeutics

1 year ago - GlobeNewsWire

Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

Preclinical Data Show Potential to Overcome Resistance to Key KRAS-G12C Therapeutic Compounds

1 year ago - GlobeNewsWire

Qualigen Therapeutics, Inc. Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update

CARLSBAD, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN Qualigen Therapeutics, Inc.), a diversified life sciences company focused on developing treatments for adul...

1 year ago - GlobeNewsWire

Qualigen Therapeutics' Pan-RAS Inhibitor Program Highlighted in Two Abstracts at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

Abstracts Feature Preclinical Data in (1) Pancreatic Cancer and (2) Luminal B Breast Cancer

1 year ago - GlobeNewsWire

Qualigen Therapeutics, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-K Filing

CARLSBAD, Calif., April 21, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for a...

1 year ago - GlobeNewsWire

Qualigen Therapeutics Announces Four Posters on QN-302 Presented at the American Association of Cancer Research (AACR) 2023 Annual Meeting in Orlando, FL

CARLSBAD, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for a...

1 year ago - GlobeNewsWire

Qualigen Therapeutics Presents Data On QN-247 in Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, FL

In V ivo Efficacy Study Demonstrates QN-247 as Potential Therapeutic Approach in Rare Breast Cancer Type

1 year ago - GlobeNewsWire

Composition of Matter Patent for QN-302 Granted by United States Patent and Trademark Office

CARLSBAD, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for a...

1 year ago - GlobeNewsWire